香港上市的中国生物制药(01177.HK)于周二披露重大收购计划。公司将斥资不超过9.5092亿美元,收购总部位于上海的LaNova Medicines剩余95.09%股权。这笔交易凸显中国生物制药的战略布局,旨在强化其在医药领域的市场地位。
香港上市的中国生物制药(01177.HK)于周二披露重大收购计划。公司将斥资不超过9.5092亿美元,收购总部位于上海的LaNova Medicines剩余95.09%股权。这笔交易凸显中国生物制药的战略布局,旨在强化其在医药领域的市场地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.